|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Naidoo J, Sima CS, Rodriguez K, Busby N,
Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME and Yu HA:
Epidermal growth factor receptor exon 20 insertions in advanced
lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Cancer. 121:3212–3220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Harman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takeuchi S and Yano S: Clinical
significance of epidermal growth factor receptor tyrosine kinase
inhibitors: Sensitivity and resistance. Respir Investig.
52:348–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jackman D, Pao W, Riely GJ, Engelman JA,
Kris MG, Jänne PA, Lynch T, Johnson BE and Miller VA: Clinical
definition of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar
|
|
10
|
O'Connor L, Strasser A, O'Reilly LA,
Hausmann G, Adams JM, Cory S and Huang DC: Bim: A novel member of
the Bcl-2 family that promotes apoptosis. EMBO J. 17:384–395. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harada H and Grant S: Targeting the
regulatory machinery of BIM for cancer therapy. Crit Rev Eukaryot.
Gene Expr. 22:117–129. 2012.
|
|
12
|
Bouillet P, Metcalf D, Huang DC, Tarlinton
DM, Kay TW, Köntgen F, Adams JM and Strasser A: Proapoptotic Bcl-2
relative Bim required for certain apoptotic responses, leukocyte
homeostasis, and to preclude autoimmunity. Science. 286:1735–1738.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bouillet P, Purton JF, Godfrey DI, Zhang
LC, Coultas L, Puthalakath H, Pellegrini M, Cory S, Adams JM and
Strasser A: BH3-only Bcl-2 family member Bim is required for
apoptosis of autoreactive thymocytes. Nature. 415:922–926. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong YX, Somwar R, Politi K, Balak M,
Chmielecki J, Jiang X and Pao W: Induction of BIM is essential for
apoptosis triggered by EGFR kinase inhibitors in mutant
EGFR-dependent lung adenocarcinomas. PLoS Med. 4:e2942007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cardona AF, Rojas L, Wills B, Arrieta O,
Carranza H, Vargas C, Otero J, Corrales-Rodrigues L, Martin C,
Reguart N, et al: BIM deletion polymorphisms in Hispanic patients
with non-small cell lung cancer carriers of EGFR mutations.
Oncotarget. 7:68933–68942. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2012. View
Article : Google Scholar :
|
|
17
|
Lee JY, Ku BM, Lim SH, Lee MY, Kim H, Kim
M, Kim S, Jung HA, Sun JM, Ahn JS, et al: The BIM deletion
polymorphism and its clinical implication in patients with
EGFR-mutant non-small-cell lung cancer treated with EGFR tyrosine
kinase inhibitors. J Thorac Oncol. 10:903–909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Faber AC, Corcoran RB, Ebi H, Sequist LV,
Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, et
al: BIM expression in treatment-naive cancers predicts
responsiveness to kinase inhibitors. Cancer Discov. 1:352–365.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Filippova N, Yang X, Wang Y, Gillespie GY,
Langford C, King PH, Wheeler C and Nabors LB: The RNA-binding
protein HuR promotes glioma growth and treatment resistance. Mol
Cancer Res. 9:648–659. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brennan CM and Steitz JA: HuR and mRNA
stability. Cell Mol Life Sci. 58:266–277. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heinonen M, Fagerholm R, Aaltonen K,
Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C,
Nevanlinna H and Ristimäki A: Prognostic role of HuR in hereditary
breast cancer. Clin Cancer Res. 13:6959–6963. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giammanco A, Blanc V, Montenegro G, Klos
C, Xie Y, Kennedy S, Luo J, Chang SH, Hla T, Nalbantoglu I, et al:
Intestinal epithelial HuR modulates distinct pathways of
proliferation and apoptosis and attenuates small intestinal and
colonic tumor development. Cancer Res. 74:5322–5335. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Erkinheimo TL, Lassus H, Sivula A,
Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R and Ristimäki A:
Cytoplasmic HuR expression correlates with poor outcome and with
cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer
Res. 63:7591–7594. 2003.PubMed/NCBI
|
|
24
|
Denkert C, Koch I, von Keyserlingk N,
Noske A, Niesporek S, Dietel M and Weichert W: Expression of the
ELAV-like protein HuR in human colon cancer: Association with tumor
stage and cyclooxygenase-2. Mod Path. 19:1261–1269. 2006.
View Article : Google Scholar
|
|
25
|
Costantino CL, Witkiewicz AK, Kuwano Y,
Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M
and Brody JR: The role of HuR in gemcitabine efficacy in pancreatic
cancer: HuR upregulates the expression of the gemcitabine
metabolizing enzyme deoxycytidine kinase. Cancer Res. 69:4567–4572.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beasley MB, Brambilla E and Travis WD: The
2004 World Health Organization classification of lung tumors. Semin
Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De K I, Mirhosseini M, Lau F, Thai V,
Downing M, Quan H, Lesperance M and Yang J: Conversion of Karnofsky
Performance Status (KPS) and Eastern Cooperative Oncology Group
Performance Status (ECOG) to Palliative Performance Scale (PPS),
and the interchangeability of PPS and KPS in prognostic tools. J
Palliat Care. 29:163–169. 2013.
|
|
28
|
Yu X, Zhan X, D'Costa J, Tanavde VM, Ye Z,
Peng T, Malehorn MT, Yang X, Civin CI and Cheng L: Lentiviral
vectors with two independent internal promoters transfer high-level
expression of multiple transgenes to human hematopoietic
stem-progenitor cells. Mol Ther. 7:827–838. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar
|
|
30
|
Wang J, Li D, Wang B and Wu Y: Predictive
and prognostic significance of cytoplasmic expression of ELAV-like
protein HuR in invasive breast cancer treated with neoadjuvant
chemotherapy. Breast Cancer Res Treat. 141:213–224. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maimaiti Y, Dong L, Aili A, Maimaitiaili
M, Huang T and Abudureyimu K: Bim may be a poor prognostic
biomarker in breast cancer patients especially in those with
luminal A tumors. Cancer Biomarkers. 19:411–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nature Rev Mol Cell Biol.
15:49–63. 2014. View Article : Google Scholar
|
|
33
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sarosiek KA and Letai A: Directly
targeting the mitochondrial pathway of apoptosis for cancer therapy
using BH3 mimetics-recent successes, current challenges and future
promise. FEBS J. 283:3523–3533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu DW, Chen CY, Chu CL and Lee H: Paxillin
confers resistance to tyrosine kinase inhibitors in EGFR-mutant
lung cancers via modulating BIM and Mcl-1 protein stability.
Oncogene. 35:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li H, Zhou S, Li X, Wang D, Wang Y, Zhou C
and Schmid-Bindert G: Gefitinib-resistance is related to BIM
expression in non-small cell lung cancer cell lines. Cancer Biother
Radiopharm. 28:115–123. 2013. View Article : Google Scholar :
|
|
38
|
Costa C, Molina MA, Drozdowskyj A,
Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervias R,
Massuit B, Wei J, Moran T, et al: The impact of EGFR T790M
mutations and BIM mRNA expression on outcome in patients with
EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the
randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2010.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang D, Wang M, Hu C, Shuang T, Zhou Y and
Yan X: Expression of the ELAV-like protein HuR in the cytoplasm is
associated with endometrial carcinoma progression. Tumor Biol.
35:11939–11947. 2014. View Article : Google Scholar
|
|
40
|
Wang J, Guo Y, Chu H, Guan Y, Bi J and
Wang B: Multiple functions of the RNA-binding protein HuR in cancer
progression, treatment responses and prognosis. Int J Mol Sci.
14:10015–10041. 2014. View Article : Google Scholar
|
|
41
|
Zhu H, Berkova Z, Mathur R, Sehgal L,
Khashab T, Tao RH, Ao X, Feng L, Sabichi AL, Blechacz B, et al: HuR
suppresses Fas expression and correlates with patient outcome in
liver cancer. Mol Cancer Res. 13:809–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Romeo C, Weber MC, Zarei M, DeCicco D,
Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober
N, et al: HuR contributes to TRAIL resistance by restricting death
receptor 4 expression in pancreatic cancer cells. Mol Cancer Res.
14:599–611. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Prislei S, Martinelli E, Mariani M,
Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G and
Ferlini C: MiR-200c and HuR in ovarian cancer. BMC Cancer.
13:722013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sawicki JA, Huang YH, Brody JR, Getts RC,
Rhodes K and Gerhart J: Abstract 3542: Inhibition of HuR
effectively suppresses ovarian tumor growth in mice. Cancer Res.
75(15 Suppl): Abstract 3542. 2015. View Article : Google Scholar
|
|
45
|
Wang J, Wang B, Bi J and Zhang C:
Cytoplasmic HuR expression correlates with angiogenesis,
lymphangiogenesis, and poor outcome in lung cancer. Med Oncol.
28:S577–S585. 2011. View Article : Google Scholar
|
|
46
|
Wang J, Zhao W, Guo Y, Zhang B, Xie Q,
Xiang D, Gao J, Wang B and Chen Z: The expression of RNA-binding
protein HuR in non-small cell lung cancer correlates with vascular
endothelial growth factor-C expression and lymph node metastasis.
Oncology. 76:420–429. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vigouroux C, Casse JM, Battaglia-Hsu SF,
Brochin L, Luc A, Paris C, Lacomme S, Gueant JL, Vignaud JM and
Gauchotte G: Methyl(R217)HuR and MCM6 are inversely correlated and
are prognostic markers in non small cell lung carcinoma. Lung
Cancer. 89:189–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Giaginis C, Sampani A, Kotta-Loizou I,
Giannopoulou I, Danas E, Politi E, Tsourouflis G, Kouraklis G,
Patsouris E, Keramopoulos A, et al: Elevated hu-antigen receptor
(HuR) expression is associated with tumor aggressiveness and poor
prognosis but not with COX-2 expression in invasive breast
carcinoma patients. Pathol Oncol Res. 24:631–640. 2018. View Article : Google Scholar
|
|
49
|
Wang W, Caldwell MC, Lin S, Furneaux H and
Gorospe M: HuR regulates cyclin A and cyclin B1 mRNA stability
during cell proliferation. EMBO J. 19:2340–2350. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fernau NS, Fugmann D, Leyendecker M,
Reimann K, Grether-Beck S, Galban S, Ale-Agha N, Krutmann J and
Klotz LO: Role of HuR and p38MAPK in ultraviolet
B-induced post-transcriptional regulation of COX-2 expression in
the human keratinocyte cell line HaCaT. J Biol Chem. 285:3896–3904.
2010. View Article : Google Scholar
|
|
51
|
Serini S, Fasano E, Piccioni E, Monego G,
Cittadini AR, Celleno L, Ranelletti FO and Calviello G: DHA induces
apoptosis and differentiation in human melanoma cells in vitro:
Involvement of HuR-mediated COX-2 mRNA stabilization and β-catenin
nuclear translocation. Carcinogenesis. 33:164–173. 2012. View Article : Google Scholar
|
|
52
|
Wang W, Furneaux H, Cheng H, Caldwell MC,
Hutter D, Liu Y, Holbrook N and Gorospe M: HuR regulates p21 mRNA
stabilization by UV light. Mol Cell Biol. 20:760–769. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hung CM, Huang WC, Pan HL, Chien PH, Lin
CW, Chen LC, Chien YF, Lin CC, Leow KH, Chen WS, et al: Hepatitis B
virus X upregulates HuR protein level to stabilize HER2 expression
in hepatocellular carcinoma cells. Biomed Res Int. 2014:8274152014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ishimaru D, Ramalingam S, Sengupta TK,
Bandyopadhyay S, Dellis S, Tholanikunnel BG, Fernandes DJ and
Spicer EK: Regulation of Bcl-2 expression by HuR in HL60 leukemia
cells and A431 carcinoma cells. Mol Cancer Res. 7:1354–1366. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Spicer EK, Ishimaru D, Ramalingam S,
Tholanikunnel BG and Fernandes DJ: Role of HuR in the regulation of
bcl-2 mRNA stability in human HL60 leukemia cells. FASEB J. 22(1
Suppl): 786.52008.
|
